Telix Debt To Equity from 2010 to 2024

TLX Stock   15.35  0.20  1.32%   
Telix Pharmaceuticals Debt To Equity yearly trend continues to be fairly stable with very little volatility. Debt To Equity is likely to outpace its year average in 2024. Debt To Equity is a measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets. View All Fundamentals
 
Debt To Equity  
First Reported
2010-12-31
Previous Quarter
0.06160055
Current Value
0.0647
Quarterly Volatility
2.42944021
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Telix Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Telix Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 7.1 M, Interest Expense of 7.1 M or Selling General Administrative of 57.5 M, as well as many indicators such as Price To Sales Ratio of 0.41, Days Sales Outstanding of 45.23 or Invested Capital of 0.0. Telix financial statements analysis is a perfect complement when working with Telix Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Telix Pharmaceuticals Correlation against competitors.

Latest Telix Pharmaceuticals' Debt To Equity Growth Pattern

Below is the plot of the Debt To Equity of Telix Pharmaceuticals Limited over the last few years. It is a measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets. Telix Pharmaceuticals' Debt To Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Telix Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 0.00 %10 Years Trend
Pretty Stable
   Debt To Equity   
       Timeline  

Telix Debt To Equity Regression Statistics

Arithmetic Mean(0.96)
Geometric Mean0.68
Coefficient Of Variation(253.22)
Mean Deviation1.63
Median(0.52)
Standard Deviation2.43
Sample Variance5.90
Range10.2019
R-Value0.28
Mean Square Error5.86
R-Squared0.08
Significance0.31
Slope0.15
Total Sum of Squares82.63

Telix Debt To Equity History

2024 0.0647
2023 0.0616
2022 0.13
2021 1.18
2020 0.0279
2019 -0.67
2018 -0.52

About Telix Pharmaceuticals Financial Statements

Telix Pharmaceuticals investors use historical fundamental indicators, such as Telix Pharmaceuticals' Debt To Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Telix Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Debt To Equity 0.06  0.06 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Telix Stock Analysis

When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.